Texas Permanent School Fund Harmony Biosciences Holdings, Inc. Transaction History

Texas Permanent School Fund

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	SELL	$28.81 - $33.01 $16,882 - $19,343	-586 Reduced 2.04%	28,120 $848,000
Q1 2024 May 03, 2024	BUY	$29.93 - $35.06 $15,473 - $18,126	517 Added 1.83%	28,706 $963,000
Q4 2023 Feb 08, 2024	SELL	$19.2 - $33.78 $6,432 - $11,316	-335 Reduced 1.17%	28,189 $910,000
Q3 2023 Nov 09, 2023	BUY	$31.89 - $39.03 $68,276 - $83,563	2,141 Added 8.12%	28,524 $934,000
Q2 2023 Aug 07, 2023	SELL	$30.5 - $37.4 $6,557 - $8,041	-215 Reduced 0.81%	26,383 $928,000
Q1 2023 May 01, 2023	BUY	$30.8 - $53.92 $205,097 - $359,053	6,659 Added 33.4%	26,598 $868,000
Q4 2022 Feb 07, 2023	SELL	$45.4 - $60.91 $60,790 - $81,558	-1,339 Reduced 6.29%	19,939 $1.1 Million
Q3 2022 Oct 25, 2022	BUY	$42.06 - $55.45 $194,863 - $256,899	4,633 Added 27.83%	21,278 $942,000
Q2 2022 Aug 08, 2022	BUY	$33.54 - $52.15 $16,032 - $24,927	478 Added 2.96%	16,645 $812,000
Q1 2022 May 06, 2022	SELL	$33.14 - $51.13 $9,113 - $14,060	-275 Reduced 1.67%	16,167 $787,000
Q4 2021 Feb 08, 2022	BUY	$34.09 - $43.91 $560,507 - $721,968	16,442 New	16,442 $701,000

243

45.2M

108K

49.2K

Ticker HRMY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,161,400
Market Cap $2.04B
Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...

Get notified when there are updates to the investment portfolio of Texas Permanent School Fund, based on Form 13F filings with the SEC.

Stay updated on Texas Permanent School Fund with notifications on news.